WHO ICTRP trial
Study on the effects of an OCT2/MATE1 substrate (metformin) and inhibitor…
NL-OMON20484 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON20484 |
|---|---|
| Public title | Study on the effects of an OCT2/MATE1 substrate (metformin) and inhibitor (cimetidine) on the exposure of trifluridine/tipiracil (Lonsurf®) in patients with metastatic colorectal cancer (mCRC). |
| Scientific title | Study on the effects of an OCT2/MATE1 substrate (metformin) and inhibitor (cimetidine) on the exposure of trifluridine/tipiracil (Lonsurf®) in patients with metastatic colorectal cancer (mCRC). |
| Primary sponsor | Erasmus MC |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Conditions | metastatic colorectal cancer with an indication for Lonsurf treatment |
| Interventions | Patients treated with Lonsurf will be treated with metformin and cimetidine for 7 and 5 consecutive days respectively. |
| Registration date | Oct 4, 2019 |
| Target size | 18 |
| Secondary IDs | NL8067;Stichting BEBO en EMC : METC 19-0560 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: